Skip to main content

Curcumin and Ursolic Acid for the Treatment of Prostate Cancer

Trial Status: Approved

This phase I trial investigates the side effects of curcumin and ursolic acid, as well as their rate of absorption in the blood (bioavailability), their absorption in the prostate, and their interactions and effect within the body in patients with prostate cancer. Dietary supplements, such as curcumin and ursolic acid, may slow the growth of prostate cancer. This trial may help researchers learn if a combination of curcumin and ursolic acid has greater combined (synergistic) absorption in the body, which may lead to future clinical trials and ultimately to a safe and effective treatment in patients diagnosed with prostate cancer to reduce the progression of disease.

Inclusion Criteria

  • Have proven diagnosis of prostate cancer with Gleason group 3 or lower and planning to undergo radical prostatectomy
  • Be able to give informed consent
  • Able to stop supplements

Exclusion Criteria

  • Unable to give informed consent
  • High-risk prostate cancer or suspected metastasis
  • Unable to swallow pills
  • Unable to stop supplements

Texas

San Antonio
Cancer Therapy and Research Center at The UT Health Science Center at San Antonio
Status: APPROVED
Contact: Michael A. Liss
Phone: 210-567-5676

PRIMARY OBJECTIVES:

I. Evaluate the bioavailability and safety of curcumin, ursolic acid, and their combination in a phase 1 clinical trial using a pharmacokinetic approach.

II. Determine levels of ursolic acid (UA), curcumin (CURC), and metabolites within the prostate as the target organ.

III. To identify NFkappaB/Stat3 as the target biologic signature associated with the combinatorial activity of phytonutrients in prostate tissue.

OUTLINE: Patients are assigned to 1 of 3 cohorts.

COHORT 1: Patients receive ursolic acid orally (PO) twice daily (BID) for 7 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care prostatectomy.

COHORT 2: Patients receive curcumin PO BID for 7 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care prostatectomy.

COHORT 3: Patients receive ursolic acid PO BID and curcumin PO BID for 7 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care prostatectomy.

Trial Phase Phase I

Trial Type Treatment

Lead Organization
Cancer Therapy and Research Center at The UT Health Science Center at San Antonio

Principal Investigator
Michael A. Liss

  • Primary ID CTMS 19-0126
  • Secondary IDs NCI-2020-04460, HSC20190735HU
  • Clinicaltrials.gov ID NCT04403568